Trial Profile

Assessment if a Daily SMS (Short Message System) Reminder Improves the Adherence of COPD Patients to Therapy With Spiriva 18 Microgram.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tiotropium bromide (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

14 Dec 2011 Actual patient number is 96 as reported by ClinicalTrials.gov.
14 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
19 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com